Data / New clinical trials / Company sponsors / PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co. trials: 43 (2026)
Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).
ClinicalTrials.gov lists 43 trials with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor, 12 of them recruiting or not yet recruiting.
The full list. Clinical trials led by PersonGen BioTherapeutics (Suzhou) Co., Ltd.: 43 rows for $5, every trial on ClinicalTrials.gov.
$10 of credit on sign-up, no card. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.
For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/company/persongen-biotherapeutics-suzhou-co-ltd, and every list with its row count and price is at https://specstream.ai/data/lists.json.
The request: Every clinical trial PersonGen BioTherapeutics (Suzhou) Co., Ltd. leads on ClinicalTrials.gov, with phase, status, conditions and sites, and each new one.
SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.
- Trials
- 43
- Recruiting or not yet
- 12
- Read on
- November 19, 2026
Trials
The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.
| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
|---|---|---|---|---|---|---|---|---|
| June 3, 2026 | NCT07623681 | Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory... | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | Not yet recruiting | CD7+ T-ALL/LBL | 12 | clinicaltrials.gov |
| January 14, 2026 | NCT07338604 | Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Recruiting | Hematolymphoid Malignancies | 15 | clinicaltrials.gov |
| December 31, 2025 | NCT07312630 | Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Recruiting | Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult | 19 | clinicaltrials.gov |
| December 16, 2025 | NCT07284927 | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | Recruiting | Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 10 | clinicaltrials.gov |
| September 23, 2025 | NCT07188610 | PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 2 | Recruiting | CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | 100 | clinicaltrials.gov |
| May 21, 2025 | NCT06982547 | Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA) | 24 | clinicaltrials.gov |
| May 21, 2025 | NCT06982534 | Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection. | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Not yet recruiting | Systemic Sclerosis (SSc) | 24 | clinicaltrials.gov |
| May 14, 2025 | NCT06970951 | Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies, Systemic Sclerosis | 15 | clinicaltrials.gov |
| March 12, 2025 | NCT06871644 | Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not applicable | Not yet recruiting | Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria | 18 | clinicaltrials.gov |
| May 16, 2024 | NCT06417398 | Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Unknown | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome, Rheumatoid... | 10 | clinicaltrials.gov |
| April 12, 2024 | NCT06361745 | Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not applicable | Unknown | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, IgG4 Related Disease, Primary... | 10 | clinicaltrials.gov |
| February 26, 2024 | NCT06279026 | UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not applicable | Recruiting | Relapsed/Refractory Multiple Myeloma | 15 | clinicaltrials.gov |
| October 23, 2023 | NCT06092047 | UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Recruiting | CD19-positive Relapsed or Refractory B-cell Malignancies | 10 | clinicaltrials.gov |
| February 16, 2023 | NCT05731219 | UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | Unknown | Relapsed/Refractory Acute Myeloid Leukemia | 18 | clinicaltrials.gov |
| February 10, 2023 | NCT05722171 | Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Unknown | Relapsed/Refractory Acute Myeloid Leukemia | 10 | clinicaltrials.gov |
| September 30, 2022 | NCT05562024 | TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | Recruiting | B7-H3-positive Relapsed/ Refractory Neuroblastoma | 24 | clinicaltrials.gov |
| June 27, 2022 | NCT05432401 | TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Unknown | FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia | 18 | clinicaltrials.gov |
| January 13, 2022 | NCT05190185 | A Clinical Trial of TAA06 Injection in Advanced Solid Tumors | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | Unknown | Malignant Melanoma, Lung Cancer, or Colorectal Cancer | 18 | clinicaltrials.gov |
| December 28, 2021 | NCT05170568 | PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | Unknown | CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies | 22 | clinicaltrials.gov |
| August 24, 2021 | NCT05017883 | TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not applicable | Unknown | CAR, Acute Myeloid Leukemia | 5 | clinicaltrials.gov |
| April 29, 2021 | NCT04864821 | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Unknown | Osteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer | 24 | clinicaltrials.gov |
| March 8, 2021 | NCT04785833 | CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not applicable | Unknown | T-ALL | 20 | clinicaltrials.gov |
| January 11, 2021 | NCT04702841 | CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Unknown | CAR, Malignant Tumors | 8 | clinicaltrials.gov |
| January 7, 2021 | NCT04700319 | CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Unknown | CAR | 30 | clinicaltrials.gov |
| January 5, 2021 | NCT04692948 | TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not applicable | Unknown | CAR, Acute Myeloid Leukemia | 5 | clinicaltrials.gov |
By phase
| Phase | Trials |
|---|---|
| Early phase 1 | 17 |
| Phase 1 | 9 |
| Phase 1/2 | 8 |
| Phase 2 | 1 |
| Not applicable | 8 |
By status
| Status | Trials |
|---|---|
| Unknown | 30 |
| Recruiting | 7 |
| Not yet recruiting | 5 |
| Completed | 1 |
Conditions
| Condition group | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 7 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
| Lymphoma, Mantle-Cell | 5 |
| Lymphoma, Follicular | 5 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Scleroderma, Systemic | 4 |
| Lymphoma, Non-Hodgkin | 3 |
| Arthritis, Rheumatoid | 3 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Leukemia, Prolymphocytic, B-Cell | 3 |
| Stomach Neoplasms | 3 |
| Colorectal Neoplasms | 3 |
| Lupus Erythematosus, Systemic | 3 |
| Myositis | 3 |
| Multiple Myeloma | 3 |
| Neoplasms | 2 |
| Carcinoma, Hepatocellular | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Pancreatic Neoplasms | 2 |
| Immunoblastic Lymphadenopathy | 2 |
| Lymphoma, Extranodal NK-T-Cell | 2 |
| Enteropathy-Associated T-Cell Lymphoma | 2 |
| Lung Neoplasms | 2 |
| Leukemia, B-Cell | 1 |
Where the register publishes
U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown. Free to quote with credit and a link. Copying in bulk needs a data licence. Spot a wrong value? Write to [email protected] with the link to this page.
$10 of credit on sign-up, no card.
Business lists in the United States
- Nursing services in the United States
- Social security law firms in the United States
- Appraisers in the United States
- Computer hardware companies in the United States
- Gluten free restaurants in the United States
- Mortgage lenders in the United States